Cancer BiologybioRxivPreprint
Primary CD34+ cells of patients with VEXAS syndrome are highly sensitive to targeted treatment with TAK-243 and pevonedistat
Daniel Nowak, Marie Demmerle, Alessa Klär…·Nanni Schmitt
This study shows that VEXAS patient-derived CD34+ cells are more sensitive to TAK-243 and pevonedistat than MDS and healthy controls, suggesting potential targeted therapy.
DOI 10.1101/2025.05.22.653244